Navigation Links
New strategy for inhibiting virus replication
Date:8/14/2009

B>

A cell contains numerous variants of cyclophilins that are inhibited by cyclosporin and cyclosporin derivatives. The research team from Heidelberg analyzed liver cells to determine which cyclophilin is critical for hepatitis C virus replication. They found that only blocking cyclophilin A leads complete inhibition of virus replication and this cyclophilin is also the target of DEBIO-025.

Two complementary effects are responsible for the inhibition of hepatitis C virus replication: cyclophilin A is required both for the formation of the viral replication machinery and for the activity of a viral enzyme that is essential for the assembly of infectious virus particles. Inhibiting cyclophilin A with DEBIO-025 thus blocks hepatitis C virus replication from two different sides. By contrast, blocking cyclophilin B had no effect.

"The therapeutic potential of inhibiting cellular factors essential for virus replication has thus far hardly been tapped," explains Professor Bartenschlager. "But this approach has the major advantage that resistance arises less frequently and to a lesser extent in comparison to therapies directly targeting viral factors."


'/>"/>

Contact: Dr. Ralf Bartenschlager
Ralf_Bartenschlager@med.uni-heidelberg.de
062-215-64569
University Hospital Heidelberg
Source:Eurekalert

Page: 1 2

Related biology news :

1. A combined tooth-venom arsenal revealed as key to Komodo dragons hunting strategy
2. New therapeutic strategy could target toxic protein in most patients with Huntingtons disease
3. Therapeutic hypothermia is promising strategy to minimize tissue damage
4. RNA research strategy for Europe takes shape
5. Hope for a rabies eradication strategy in Africa
6. Mitochondria could be a target for therapeutic strategy for Alzheimers disease patients
7. GUMC researchers hone in on new strategy to treat common infection
8. Effects of anthropogenic sound on marine mammals -- a research strategy
9. Scientists uncover Ebola cell-invasion strategy
10. New study raises concerns about proposed mitigation strategy for marine bycatch
11. Novel therapeutic strategy for colon cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2015)... NexID Biometrics LLC, whose spoof-mitigation technology boosts protection ... beginning of shipments of version 2.0 of its industry ... in Potsdam, N.Y. , is making ... here today at the Walter E. Washington Convention Center. ... boosts the accuracy rate range to 96.5 to 99.5 ...
(Date:3/23/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet, ... March 30 th . The new ... York markets. Gino Pereira ... new ad campaign following the recent initial shipment of Wocket ...
(Date:3/19/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, announces its biometric payment technology, the Wocket® smart ... week on Washington DC,s Fox 5 ... "The Next Great Thing", host Laura Evans calls ... ,a really big breakthrough in mobile payment.,  ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... Institutet have identified an important mechanism that regulates how ... cell. The study is published in the latest issue ... help us develop new drugs for things like neurological ... most organs of the body, old cells are continually ...
... To a tiny tadpole, life boils down to two basic ... The more a tadpole eats, the faster it grows big ... being active, which ups the odds of becoming someone else's ... activity levels in response to predation risk, but new research ...
... discovered how the brain creates a scent symphony from signals ... researchers found that nerve cells in the brain's olfactory bulb ... do not perceive complex scent mixtures as single objects, such ... cells, or neurons, detect the host of chemical compounds that ...
Cached Biology News:New stem-cell findings can help the body to cure itself 2Time of day tempers tadpoles' response to predators 2Researchers show how brain decodes complex smells 2
(Date:4/21/2015)... April 21, 2015 Ampio Pharmaceuticals, Inc. (NYSE ... investor call on Thursday, April 23, 4:30 p.m. ET. ... as follows: Investor call information: ... 789-4877 International toll number: (925) 418-7845 Participant Passcode: 32888538 ... Tina Amirkiai , tina.amirkiai@fleishman.com . ...
(Date:4/21/2015)... , April 21, 2015  Cryoport, ... of advanced cryogenic logistics solutions for the ... stem cells, cell lines, clinical research organizations, ... that Dr. Mark W. Sawicki , ... 3rd Annual BioLogistics Summit in San ...
(Date:4/21/2015)... April 21, 2015  scPharmaceuticals, Inc., a ... products for subcutaneous delivery, announced today that ... its investigational proprietary drug product, Furosemide Injection ... with congestive heart failure. Concurrently ... a proprietary patch pump.  The patch pump ...
(Date:4/21/2015)... Bruno, CA (PRWEB) April 21, 2015 ... CRO, will sponsor and exhibit at the ACRP 2015 ... Salt Lake City, Utah. The Association of Clinical Research ... annual clinical research conference solely focused on the conduct ... membership, training and development, and widely recognized industry certifications. ...
Breaking Biology Technology:Ampio Announces Investor Call on Thursday, April 23, 4:30 p.m. ET 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 3scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 2scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 3PRC Clinical Sponsors The ACRP 2015 Global Conference And Meets Biotech Companies in the Salt Lake City Area. 2
... NOVATO, Calif., June 1 Raptor Pharmaceuticals Corp. ... today announced that it has dosed the first ... in collaboration with the University of California, ... delayed-release cysteamine bitartrate ("DR Cysteamine") capsules in nephropathic ...
... ... Mass Spectrometry-based biomarker discovery will be demonstrated at the 57th ASMS Conference on Mass ... , ... (PRWEB) June 1, 2009 -- Genedata , a leading provider of in silico ...
... from the first time point measured (1.5 hours) through ... Shire plc (LSE: SHP, Nasdaq: ... announced that the US Food and Drug Administration (FDA) ... its once-daily Attention Deficit Hyperactivity Disorder (ADHD) treatment VYVANSE ...
Cached Biology Technology:Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 2Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 3Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 4Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 5Genedata Launches Expressionist with Expanded Mass Spectrometry Biomarker Discovery Capabilities 2Genedata Launches Expressionist with Expanded Mass Spectrometry Biomarker Discovery Capabilities 3FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 2FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 3FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 4FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 5FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 6FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 7
Anti-TNKS2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
Rabbit Anti-Human Janus Kinase 2 (JAK2 Polyclonal Antibody Family: Protein Kinase Sub-Family: TYK2/JAK Applications: ELISA, Western Blot...
Goat polyclonal to Lipocalin 2...
Human GCP-2 is a member of the CXC family of chemokines. It also promotes neutrophil chemotaxis and deganulation. GF063 is an 8.0 kDa protein containing 73 amino acid residues....
Biology Products: